2025 Q3 -tulosraportti
41 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
10 520
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | AVA | NON | ||
| 34 | NON | NON | ||
| 1 396 | NON | NON | ||
| 1 637 | NON | DDB | ||
| 909 | NRD | DDB |
Ylin
11,6VWAP
Alin
11VaihtoMäärä
1,1 99 592
VWAP
Ylin
11,6Alin
11VaihtoMäärä
1,1 99 592
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.
·1 päivä sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now
·1 päivä sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
·1 päivä sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅
·1 päivä sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?- ·2 päivää sittenIt's funny with such an illiquid stock like this one. How does one find a fair price when it is so largely defined by individual buyers/sellers? If there is no news, there is no buying pressure and it slowly trickles down. If then someone places a large buy or sell order, it can significantly change the price because there are so few bidders. I really need to get used to not fixating on the current price and just think long-term. Because it will surely be good there.
·3 päivää sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
41 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.
- ·1 päivä sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now·1 päivä sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
- ·1 päivä sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅·1 päivä sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?
- ·2 päivää sittenIt's funny with such an illiquid stock like this one. How does one find a fair price when it is so largely defined by individual buyers/sellers? If there is no news, there is no buying pressure and it slowly trickles down. If then someone places a large buy or sell order, it can significantly change the price because there are so few bidders. I really need to get used to not fixating on the current price and just think long-term. Because it will surely be good there.
- ·3 päivää sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
10 520
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | AVA | NON | ||
| 34 | NON | NON | ||
| 1 396 | NON | NON | ||
| 1 637 | NON | DDB | ||
| 909 | NRD | DDB |
Ylin
11,6VWAP
Alin
11VaihtoMäärä
1,1 99 592
VWAP
Ylin
11,6Alin
11VaihtoMäärä
1,1 99 592
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
41 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.
- ·1 päivä sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now·1 päivä sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
- ·1 päivä sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅·1 päivä sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?
- ·2 päivää sittenIt's funny with such an illiquid stock like this one. How does one find a fair price when it is so largely defined by individual buyers/sellers? If there is no news, there is no buying pressure and it slowly trickles down. If then someone places a large buy or sell order, it can significantly change the price because there are so few bidders. I really need to get used to not fixating on the current price and just think long-term. Because it will surely be good there.
- ·3 päivää sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
10 520
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | AVA | NON | ||
| 34 | NON | NON | ||
| 1 396 | NON | NON | ||
| 1 637 | NON | DDB | ||
| 909 | NRD | DDB |
Ylin
11,6VWAP
Alin
11VaihtoMäärä
1,1 99 592
VWAP
Ylin
11,6Alin
11VaihtoMäärä
1,1 99 592
Välittäjätilasto
Dataa ei löytynyt